Integrity for Providers

Integrity Laboratories

Integrity Laboratories is rapidly onboarding new technologies to help clinicians manage infectious diseases. These technologies have the potential to impact health outcomes for patients with a wide variety of conditions, including bacterial vaginosis, bladder infections, lower respiratory infections, pneumonia, meningitis, and sepsis. The age range of patients who suffer from these conditions is also very wide—from neonates to the elderly.

The technologies for microbiological diagnosis have advanced rapidly due to the pressing need for tools that provide rapid detection, greater sensitivity, and more accurate diagnoses. For generations, time- and labor-intensive techniques—such as culture-based detection and sensitivity testing—followed the same basic principles, often requiring days of turnaround time and allocation of samples to multiple assays with diverse methodologies. Today, molecular methods provide speed and efficiency. Initially, the purpose of molecular microbiology was to identify microorganisms following growth in culture. However, many organisms cannot be cultured. The new goal of the field is to identify microorganisms present in specimens, without an intermediate culture step.

Molecular testing enables detection of fastidious organisms, reduces the number of missed diagnoses, and makes parallel detection of polymicrobial infections easier. In addition, molecular testing promises to be more scalable than manual culture methods and microscopy. Many applications are seeing a shift from single-organism assays to efficient and cost-saving syndromic panels.

Integrity Laboratories began testing for SARS-CoV-2 (COVID-19) under Emergency Use Authorization (EUA) on March 23.

Please direct all inquiries to for immediate review.

Click Here for CDC recommendations for Identifying Monkeypox.

FDA Authorization Letter   |   FDA EUA Summary

CARES Act Statement